Global Streptococcus Pneumoniae Vaccine Market

Streptococcus Pneumoniae Vaccine Comprehensive Study by Type (Pneumococcal Conjugate Vaccine (PCV), Pneumococcal Polysaccharide Vaccine (PPV)), Application (Clinics, Hospitals), Vaccine Type (Synflorix, Prevnar 13, Pneumovax 23), Distribution Channel (Governmental Organizations, Non-Government Organizations), End-User (Adults Above 65 Years, Children Above 2 Years) Players and Region - Global Market Outlook to 2026

Streptococcus Pneumoniae Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Streptococcus Pneumoniae Vaccine Market Scope?
The very first pneumococcal vaccine was made in the 1980s. It is on the list of the World Health Organization as one of the most important medicines. It is the safest and most effective medicine needed in any healthcare system. These vaccines are usually very safe. With this conjugated vaccine, nearly 10 percent of babies will develop redness at the injection site, difficulty sleeping, and sometimes a fever. Severe allergies are very rare. Pneumococcal vaccines are the vaccines that fight against the bacterium Streptococcus pneumoniae. The use of these can effectively prevent some cases of pneumonia, sepsis, and meningitis. Namely, there are two types of pneumococcal vaccines as conjugate vaccines and polysaccharide vaccines. These are given by injection either into a muscle area or just under the skin. The World Health Organization (WHO) commends the use of the conjugate vaccine in the routine immunization to be given to the children. This also includes people with HIV / AIDS. These vaccines are effective in healthy adults, but not entirely effective in children under the age of two and children with very poor immune function. In 2013, the World Health Organization and UNICEF launched a Global Plan of Action to Prevent and Control Pneumonia and Diarrhea (GAPPD), opening a new chapter in efforts to contain pneumonia. We are currently facing a whole new challenge, the COVID-19 pandemic. The coronavirus is responsible for respiratory illnesses and some of the infected leads develop pneumonia. Respiratory diseases such as COVID-19 very often spread through droplets from an infected person's sneeze or cough, or through contact with contaminated surfaces. Hence, poor hygiene or sanitation and overcrowding are some of the major drivers of transmission. Vaccines can prove to be one of the keys to prevention. They are the world's best for health and the very first line of defense against respiratory disease. Contrasted with the cheaper and available pneumonia vaccines like the pneumococcal vaccine, which are vital in releasing health resources and enabling herd immunity. Even so, the pneumonia vaccines like the pneumococcal vaccine do not offer protection against COVID-19. Although these vaccines are not very effective against COVID-19, vaccination against respiratory disease prevention is highly recommended for health protection. Due to the lower consumption and need for vaccines, the market is likely to grow very slowly. The global Streptococcus pneumoniae vaccine market was valued at USD 5,230 million in 2019 and is projected to reach USD 5,924.56 million by 2025, a CAGR of 2.1% from 2019 to 2025.

The Streptococcus Pneumoniae Vaccine market study is being classified by Type (Pneumococcal Conjugate Vaccine (PCV) and Pneumococcal Polysaccharide Vaccine (PPV)), by Application (Clinics and Hospitals) and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Streptococcus Pneumoniae Vaccine market throughout the predicted period.

Pfizer (United States), Sanofi (France), GSK (United Kingdom), Merck Group (Germany), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Abera (Sweden), S K Chemicals (South Korea), Beijing Minhai Biotechnology (China), Baxter International (United States), BIKEN TECHNO CORPORATION LTD (Japan), Celgene (United States), Panacea Biotec (India), Serum Institute of India (India), Genentech (United States), Genocea Biosciences (United States) and Lupin Limited (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Nuron Biotech (United States), Biogen (United States), Valneva SE (France) and Sinovac Biotech (China).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Streptococcus Pneumoniae Vaccine market by Type, Application and Region.

On the basis of geography, the market of Streptococcus Pneumoniae Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
On April 14th, 2020, Sanofi and GSK announced that they had signed a letter of intent to enter into a collaboration for the development of an adjuvant vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi would contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US. Whereas, GSK would contribute its proven pandemic adjuvant technology for the collaboration. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.

In July 2000, the American Academy of Pediatrics (AAP) and the CDC jointly recommended childhood pneumococcal immunization, since pneumococcal infections are the most common invasive bacterial infections in children in the United States. "The pneumococcal conjugate vaccine, PCV13 or Prevnar 13, is currently recommended for all children younger than 5 years of age, all adults 65 years or older, and persons 6 through 64 years of age with certain medical conditions," according to the 2014 AAP/CDC guidelines.

Influencing Market Trend
  • The Growing Trend Of Easier Access To Healthcare Facilities And The Provision Of Low-Cost Pneumonia Vaccines Has Also Attracted Several Consumers Causing The Market’s Growth

Market Drivers
  • Rising Prevalence of the Disease
  • Increase in Focus for Novel Pneumococcal Vaccines
  • Growing Government Focus on Immunization Programs
  • Awareness for Pneumococcal Disease

Opportunities
  • Growing Awareness and Development of Newer Therapies with Minimum Invasive Nature
  • The Development of the Protein Vaccines for Pneumococcal Diseases

Restraints
  • The Higher Costs That Are Associated With the Manufacturing of the Vaccines

Challenges
  • Lack of Awareness among the Older Population Regarding the Vaccines


Key Target Audience
Manufacturers of Streptococcus Pneumoniae Vaccine, Suppliers and Distributors of Streptococcus Pneumoniae Vaccine, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Pneumococcal Conjugate Vaccine (PCV)
  • Pneumococcal Polysaccharide Vaccine (PPV)
By Application
  • Clinics
  • Hospitals
By Vaccine Type
  • Synflorix
  • Prevnar 13
  • Pneumovax 23

By Distribution Channel
  • Governmental Organizations
  • Non-Government Organizations

By End-User
  • Adults Above 65 Years
  • Children Above 2 Years

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of the Disease
      • 3.2.2. Increase in Focus for Novel Pneumococcal Vaccines
      • 3.2.3. Growing Government Focus on Immunization Programs
      • 3.2.4. Awareness for Pneumococcal Disease
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Older Population Regarding the Vaccines
    • 3.4. Market Trends
      • 3.4.1. The Growing Trend Of Easier Access To Healthcare Facilities And The Provision Of Low-Cost Pneumonia Vaccines Has Also Attracted Several Consumers Causing The Market’s Growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Streptococcus Pneumoniae Vaccine, by Type, Application, Vaccine Type, Distribution Channel, End-User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Streptococcus Pneumoniae Vaccine (Value)
      • 5.2.1. Global Streptococcus Pneumoniae Vaccine by: Type (Value)
        • 5.2.1.1. Pneumococcal Conjugate Vaccine (PCV)
        • 5.2.1.2. Pneumococcal Polysaccharide Vaccine (PPV)
      • 5.2.2. Global Streptococcus Pneumoniae Vaccine by: Application (Value)
        • 5.2.2.1. Clinics
        • 5.2.2.2. Hospitals
      • 5.2.3. Global Streptococcus Pneumoniae Vaccine by: Vaccine Type (Value)
        • 5.2.3.1. Synflorix
        • 5.2.3.2. Prevnar 13
        • 5.2.3.3. Pneumovax 23
      • 5.2.4. Global Streptococcus Pneumoniae Vaccine by: Distribution Channel (Value)
        • 5.2.4.1. Governmental Organizations
        • 5.2.4.2. Non-Government Organizations
      • 5.2.5. Global Streptococcus Pneumoniae Vaccine by: End-User (Value)
        • 5.2.5.1. Adults Above 65 Years
        • 5.2.5.2. Children Above 2 Years
      • 5.2.6. Global Streptococcus Pneumoniae Vaccine Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Streptococcus Pneumoniae Vaccine (Volume)
      • 5.3.1. Global Streptococcus Pneumoniae Vaccine by: Type (Volume)
        • 5.3.1.1. Pneumococcal Conjugate Vaccine (PCV)
        • 5.3.1.2. Pneumococcal Polysaccharide Vaccine (PPV)
      • 5.3.2. Global Streptococcus Pneumoniae Vaccine by: Application (Volume)
        • 5.3.2.1. Clinics
        • 5.3.2.2. Hospitals
      • 5.3.3. Global Streptococcus Pneumoniae Vaccine by: Vaccine Type (Volume)
        • 5.3.3.1. Synflorix
        • 5.3.3.2. Prevnar 13
        • 5.3.3.3. Pneumovax 23
      • 5.3.4. Global Streptococcus Pneumoniae Vaccine by: Distribution Channel (Volume)
        • 5.3.4.1. Governmental Organizations
        • 5.3.4.2. Non-Government Organizations
      • 5.3.5. Global Streptococcus Pneumoniae Vaccine by: End-User (Volume)
        • 5.3.5.1. Adults Above 65 Years
        • 5.3.5.2. Children Above 2 Years
      • 5.3.6. Global Streptococcus Pneumoniae Vaccine Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Streptococcus Pneumoniae Vaccine (Price)
      • 5.4.1. Global Streptococcus Pneumoniae Vaccine by: Type (Price)
  • 6. Streptococcus Pneumoniae Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GSK (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck Group (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abera (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. S K Chemicals (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Beijing Minhai Biotechnology (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Baxter International (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BIKEN TECHNO CORPORATION LTD (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Celgene (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Panacea Biotec (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Serum Institute of India (India)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Genentech (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Genocea Biosciences (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Lupin Limited (India)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Streptococcus Pneumoniae Vaccine Sale, by Type, Application, Vaccine Type, Distribution Channel, End-User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Streptococcus Pneumoniae Vaccine (Value)
      • 7.2.1. Global Streptococcus Pneumoniae Vaccine by: Type (Value)
        • 7.2.1.1. Pneumococcal Conjugate Vaccine (PCV)
        • 7.2.1.2. Pneumococcal Polysaccharide Vaccine (PPV)
      • 7.2.2. Global Streptococcus Pneumoniae Vaccine by: Application (Value)
        • 7.2.2.1. Clinics
        • 7.2.2.2. Hospitals
      • 7.2.3. Global Streptococcus Pneumoniae Vaccine by: Vaccine Type (Value)
        • 7.2.3.1. Synflorix
        • 7.2.3.2. Prevnar 13
        • 7.2.3.3. Pneumovax 23
      • 7.2.4. Global Streptococcus Pneumoniae Vaccine by: Distribution Channel (Value)
        • 7.2.4.1. Governmental Organizations
        • 7.2.4.2. Non-Government Organizations
      • 7.2.5. Global Streptococcus Pneumoniae Vaccine by: End-User (Value)
        • 7.2.5.1. Adults Above 65 Years
        • 7.2.5.2. Children Above 2 Years
      • 7.2.6. Global Streptococcus Pneumoniae Vaccine Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Streptococcus Pneumoniae Vaccine (Volume)
      • 7.3.1. Global Streptococcus Pneumoniae Vaccine by: Type (Volume)
        • 7.3.1.1. Pneumococcal Conjugate Vaccine (PCV)
        • 7.3.1.2. Pneumococcal Polysaccharide Vaccine (PPV)
      • 7.3.2. Global Streptococcus Pneumoniae Vaccine by: Application (Volume)
        • 7.3.2.1. Clinics
        • 7.3.2.2. Hospitals
      • 7.3.3. Global Streptococcus Pneumoniae Vaccine by: Vaccine Type (Volume)
        • 7.3.3.1. Synflorix
        • 7.3.3.2. Prevnar 13
        • 7.3.3.3. Pneumovax 23
      • 7.3.4. Global Streptococcus Pneumoniae Vaccine by: Distribution Channel (Volume)
        • 7.3.4.1. Governmental Organizations
        • 7.3.4.2. Non-Government Organizations
      • 7.3.5. Global Streptococcus Pneumoniae Vaccine by: End-User (Volume)
        • 7.3.5.1. Adults Above 65 Years
        • 7.3.5.2. Children Above 2 Years
      • 7.3.6. Global Streptococcus Pneumoniae Vaccine Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Streptococcus Pneumoniae Vaccine (Price)
      • 7.4.1. Global Streptococcus Pneumoniae Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Streptococcus Pneumoniae Vaccine: by Type(USD Million)
  • Table 2. Streptococcus Pneumoniae Vaccine Pneumococcal Conjugate Vaccine (PCV) , by Region USD Million (2015-2020)
  • Table 3. Streptococcus Pneumoniae Vaccine Pneumococcal Polysaccharide Vaccine (PPV) , by Region USD Million (2015-2020)
  • Table 4. Streptococcus Pneumoniae Vaccine: by Application(USD Million)
  • Table 5. Streptococcus Pneumoniae Vaccine Clinics , by Region USD Million (2015-2020)
  • Table 6. Streptococcus Pneumoniae Vaccine Hospitals , by Region USD Million (2015-2020)
  • Table 7. Streptococcus Pneumoniae Vaccine: by Vaccine Type(USD Million)
  • Table 8. Streptococcus Pneumoniae Vaccine Synflorix , by Region USD Million (2015-2020)
  • Table 9. Streptococcus Pneumoniae Vaccine Prevnar 13 , by Region USD Million (2015-2020)
  • Table 10. Streptococcus Pneumoniae Vaccine Pneumovax 23 , by Region USD Million (2015-2020)
  • Table 11. Streptococcus Pneumoniae Vaccine: by Distribution Channel(USD Million)
  • Table 12. Streptococcus Pneumoniae Vaccine Governmental Organizations , by Region USD Million (2015-2020)
  • Table 13. Streptococcus Pneumoniae Vaccine Non-Government Organizations , by Region USD Million (2015-2020)
  • Table 14. Streptococcus Pneumoniae Vaccine: by End-User(USD Million)
  • Table 15. Streptococcus Pneumoniae Vaccine Adults Above 65 Years , by Region USD Million (2015-2020)
  • Table 16. Streptococcus Pneumoniae Vaccine Children Above 2 Years , by Region USD Million (2015-2020)
  • Table 17. South America Streptococcus Pneumoniae Vaccine, by Country USD Million (2015-2020)
  • Table 18. South America Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 19. South America Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 20. South America Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 21. South America Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 22. South America Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 23. Brazil Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 24. Brazil Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 25. Brazil Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 26. Brazil Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 27. Brazil Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 28. Argentina Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 29. Argentina Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 30. Argentina Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 31. Argentina Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 32. Argentina Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 33. Rest of South America Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 36. Rest of South America Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 37. Rest of South America Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 38. Asia Pacific Streptococcus Pneumoniae Vaccine, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 42. Asia Pacific Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 43. Asia Pacific Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 44. China Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 45. China Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 46. China Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 47. China Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 48. China Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 49. Japan Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 50. Japan Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 51. Japan Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 52. Japan Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 53. Japan Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 54. India Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 55. India Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 56. India Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 57. India Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 58. India Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 59. South Korea Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 60. South Korea Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 61. South Korea Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 62. South Korea Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 63. South Korea Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 64. Taiwan Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 65. Taiwan Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 66. Taiwan Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 67. Taiwan Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 68. Taiwan Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 69. Australia Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 70. Australia Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 71. Australia Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 72. Australia Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 73. Australia Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 76. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 79. Europe Streptococcus Pneumoniae Vaccine, by Country USD Million (2015-2020)
  • Table 80. Europe Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 81. Europe Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 82. Europe Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 83. Europe Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 84. Europe Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 85. Germany Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 86. Germany Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 87. Germany Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 88. Germany Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 89. Germany Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 90. France Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 91. France Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 92. France Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 93. France Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 94. France Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 95. Italy Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 96. Italy Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 97. Italy Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 98. Italy Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 99. Italy Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 100. United Kingdom Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 101. United Kingdom Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 102. United Kingdom Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 103. United Kingdom Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 104. United Kingdom Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 105. Netherlands Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 106. Netherlands Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 107. Netherlands Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 108. Netherlands Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 109. Netherlands Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 110. Rest of Europe Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 111. Rest of Europe Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 112. Rest of Europe Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 113. Rest of Europe Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 114. Rest of Europe Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 115. MEA Streptococcus Pneumoniae Vaccine, by Country USD Million (2015-2020)
  • Table 116. MEA Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 117. MEA Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 118. MEA Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 119. MEA Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 120. MEA Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 121. Middle East Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 122. Middle East Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 123. Middle East Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 124. Middle East Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 125. Middle East Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 126. Africa Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 127. Africa Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 128. Africa Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 129. Africa Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 130. Africa Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 131. North America Streptococcus Pneumoniae Vaccine, by Country USD Million (2015-2020)
  • Table 132. North America Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 133. North America Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 134. North America Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 135. North America Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 136. North America Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 137. United States Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 138. United States Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 139. United States Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 140. United States Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 141. United States Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 142. Canada Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 143. Canada Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 144. Canada Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 145. Canada Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 146. Canada Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 147. Mexico Streptococcus Pneumoniae Vaccine, by Type USD Million (2015-2020)
  • Table 148. Mexico Streptococcus Pneumoniae Vaccine, by Application USD Million (2015-2020)
  • Table 149. Mexico Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2015-2020)
  • Table 150. Mexico Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2015-2020)
  • Table 151. Mexico Streptococcus Pneumoniae Vaccine, by End-User USD Million (2015-2020)
  • Table 152. Streptococcus Pneumoniae Vaccine Sales: by Type(K Units)
  • Table 153. Streptococcus Pneumoniae Vaccine Sales Pneumococcal Conjugate Vaccine (PCV) , by Region K Units (2015-2020)
  • Table 154. Streptococcus Pneumoniae Vaccine Sales Pneumococcal Polysaccharide Vaccine (PPV) , by Region K Units (2015-2020)
  • Table 155. Streptococcus Pneumoniae Vaccine Sales: by Application(K Units)
  • Table 156. Streptococcus Pneumoniae Vaccine Sales Clinics , by Region K Units (2015-2020)
  • Table 157. Streptococcus Pneumoniae Vaccine Sales Hospitals , by Region K Units (2015-2020)
  • Table 158. Streptococcus Pneumoniae Vaccine Sales: by Vaccine Type(K Units)
  • Table 159. Streptococcus Pneumoniae Vaccine Sales Synflorix , by Region K Units (2015-2020)
  • Table 160. Streptococcus Pneumoniae Vaccine Sales Prevnar 13 , by Region K Units (2015-2020)
  • Table 161. Streptococcus Pneumoniae Vaccine Sales Pneumovax 23 , by Region K Units (2015-2020)
  • Table 162. Streptococcus Pneumoniae Vaccine Sales: by Distribution Channel(K Units)
  • Table 163. Streptococcus Pneumoniae Vaccine Sales Governmental Organizations , by Region K Units (2015-2020)
  • Table 164. Streptococcus Pneumoniae Vaccine Sales Non-Government Organizations , by Region K Units (2015-2020)
  • Table 165. Streptococcus Pneumoniae Vaccine Sales: by End-User(K Units)
  • Table 166. Streptococcus Pneumoniae Vaccine Sales Adults Above 65 Years , by Region K Units (2015-2020)
  • Table 167. Streptococcus Pneumoniae Vaccine Sales Children Above 2 Years , by Region K Units (2015-2020)
  • Table 168. South America Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2015-2020)
  • Table 169. South America Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 170. South America Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 171. South America Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 172. South America Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. South America Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 174. Brazil Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 175. Brazil Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 176. Brazil Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 177. Brazil Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 178. Brazil Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 179. Argentina Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 180. Argentina Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 181. Argentina Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 182. Argentina Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 183. Argentina Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 184. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 185. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 186. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 187. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 188. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 189. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2015-2020)
  • Table 190. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 191. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 192. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 193. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 194. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 195. China Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 196. China Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 197. China Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 198. China Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 199. China Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 200. Japan Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 201. Japan Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 202. Japan Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 203. Japan Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 204. Japan Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 205. India Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 206. India Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 207. India Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 208. India Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 209. India Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 210. South Korea Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 211. South Korea Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 212. South Korea Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 213. South Korea Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 214. South Korea Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 215. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 216. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 217. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 218. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 219. Taiwan Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 220. Australia Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 221. Australia Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 222. Australia Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 223. Australia Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 224. Australia Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 225. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 226. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 227. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 228. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 229. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 230. Europe Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2015-2020)
  • Table 231. Europe Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 232. Europe Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 233. Europe Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 234. Europe Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 235. Europe Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 236. Germany Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 237. Germany Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 238. Germany Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 239. Germany Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 240. Germany Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 241. France Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 242. France Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 243. France Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 244. France Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 245. France Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 246. Italy Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 247. Italy Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 248. Italy Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 249. Italy Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 250. Italy Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 251. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 252. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 253. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 254. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 255. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 256. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 257. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 258. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 259. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 260. Netherlands Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 261. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 262. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 263. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 264. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 265. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 266. MEA Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2015-2020)
  • Table 267. MEA Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 268. MEA Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 269. MEA Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 270. MEA Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 271. MEA Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 272. Middle East Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 273. Middle East Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 274. Middle East Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 275. Middle East Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 276. Middle East Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 277. Africa Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 278. Africa Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 279. Africa Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 280. Africa Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 281. Africa Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 282. North America Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2015-2020)
  • Table 283. North America Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 284. North America Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 285. North America Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 286. North America Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 287. North America Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 288. United States Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 289. United States Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 290. United States Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 291. United States Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 292. United States Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 293. Canada Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 294. Canada Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 295. Canada Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 296. Canada Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 297. Canada Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 298. Mexico Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2015-2020)
  • Table 299. Mexico Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2015-2020)
  • Table 300. Mexico Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2015-2020)
  • Table 301. Mexico Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2015-2020)
  • Table 302. Mexico Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2015-2020)
  • Table 303. Streptococcus Pneumoniae Vaccine: by Type(USD/Units)
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Company Basic Information, Sales Area and Its Competitors
  • Table 312. Company Basic Information, Sales Area and Its Competitors
  • Table 313. Company Basic Information, Sales Area and Its Competitors
  • Table 314. Company Basic Information, Sales Area and Its Competitors
  • Table 315. Company Basic Information, Sales Area and Its Competitors
  • Table 316. Company Basic Information, Sales Area and Its Competitors
  • Table 317. Company Basic Information, Sales Area and Its Competitors
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Streptococcus Pneumoniae Vaccine: by Type(USD Million)
  • Table 322. Streptococcus Pneumoniae Vaccine Pneumococcal Conjugate Vaccine (PCV) , by Region USD Million (2021-2026)
  • Table 323. Streptococcus Pneumoniae Vaccine Pneumococcal Polysaccharide Vaccine (PPV) , by Region USD Million (2021-2026)
  • Table 324. Streptococcus Pneumoniae Vaccine: by Application(USD Million)
  • Table 325. Streptococcus Pneumoniae Vaccine Clinics , by Region USD Million (2021-2026)
  • Table 326. Streptococcus Pneumoniae Vaccine Hospitals , by Region USD Million (2021-2026)
  • Table 327. Streptococcus Pneumoniae Vaccine: by Vaccine Type(USD Million)
  • Table 328. Streptococcus Pneumoniae Vaccine Synflorix , by Region USD Million (2021-2026)
  • Table 329. Streptococcus Pneumoniae Vaccine Prevnar 13 , by Region USD Million (2021-2026)
  • Table 330. Streptococcus Pneumoniae Vaccine Pneumovax 23 , by Region USD Million (2021-2026)
  • Table 331. Streptococcus Pneumoniae Vaccine: by Distribution Channel(USD Million)
  • Table 332. Streptococcus Pneumoniae Vaccine Governmental Organizations , by Region USD Million (2021-2026)
  • Table 333. Streptococcus Pneumoniae Vaccine Non-Government Organizations , by Region USD Million (2021-2026)
  • Table 334. Streptococcus Pneumoniae Vaccine: by End-User(USD Million)
  • Table 335. Streptococcus Pneumoniae Vaccine Adults Above 65 Years , by Region USD Million (2021-2026)
  • Table 336. Streptococcus Pneumoniae Vaccine Children Above 2 Years , by Region USD Million (2021-2026)
  • Table 337. South America Streptococcus Pneumoniae Vaccine, by Country USD Million (2021-2026)
  • Table 338. South America Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 339. South America Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 340. South America Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 341. South America Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 342. South America Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 343. Brazil Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 344. Brazil Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 345. Brazil Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 346. Brazil Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 347. Brazil Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 348. Argentina Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 349. Argentina Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 350. Argentina Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 351. Argentina Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 352. Argentina Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 353. Rest of South America Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 354. Rest of South America Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 355. Rest of South America Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 356. Rest of South America Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 357. Rest of South America Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 358. Asia Pacific Streptococcus Pneumoniae Vaccine, by Country USD Million (2021-2026)
  • Table 359. Asia Pacific Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 360. Asia Pacific Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 361. Asia Pacific Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 362. Asia Pacific Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 363. Asia Pacific Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 364. China Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 365. China Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 366. China Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 367. China Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 368. China Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 369. Japan Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 370. Japan Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 371. Japan Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 372. Japan Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 373. Japan Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 374. India Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 375. India Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 376. India Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 377. India Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 378. India Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 379. South Korea Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 380. South Korea Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 381. South Korea Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 382. South Korea Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 383. South Korea Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 384. Taiwan Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 385. Taiwan Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 386. Taiwan Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 387. Taiwan Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 388. Taiwan Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 389. Australia Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 390. Australia Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 391. Australia Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 392. Australia Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 393. Australia Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 394. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 395. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 396. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 397. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 398. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 399. Europe Streptococcus Pneumoniae Vaccine, by Country USD Million (2021-2026)
  • Table 400. Europe Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 401. Europe Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 402. Europe Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 403. Europe Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 404. Europe Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 405. Germany Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 406. Germany Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 407. Germany Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 408. Germany Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 409. Germany Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 410. France Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 411. France Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 412. France Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 413. France Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 414. France Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 415. Italy Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 416. Italy Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 417. Italy Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 418. Italy Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 419. Italy Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 420. United Kingdom Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 421. United Kingdom Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 422. United Kingdom Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 423. United Kingdom Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 424. United Kingdom Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 425. Netherlands Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 426. Netherlands Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 427. Netherlands Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 428. Netherlands Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 429. Netherlands Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 430. Rest of Europe Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 431. Rest of Europe Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 432. Rest of Europe Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 433. Rest of Europe Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 434. Rest of Europe Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 435. MEA Streptococcus Pneumoniae Vaccine, by Country USD Million (2021-2026)
  • Table 436. MEA Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 437. MEA Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 438. MEA Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 439. MEA Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 440. MEA Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 441. Middle East Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 442. Middle East Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 443. Middle East Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 444. Middle East Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 445. Middle East Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 446. Africa Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 447. Africa Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 448. Africa Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 449. Africa Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 450. Africa Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 451. North America Streptococcus Pneumoniae Vaccine, by Country USD Million (2021-2026)
  • Table 452. North America Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 453. North America Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 454. North America Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 455. North America Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 456. North America Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 457. United States Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 458. United States Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 459. United States Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 460. United States Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 461. United States Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 462. Canada Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 463. Canada Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 464. Canada Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 465. Canada Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 466. Canada Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 467. Mexico Streptococcus Pneumoniae Vaccine, by Type USD Million (2021-2026)
  • Table 468. Mexico Streptococcus Pneumoniae Vaccine, by Application USD Million (2021-2026)
  • Table 469. Mexico Streptococcus Pneumoniae Vaccine, by Vaccine Type USD Million (2021-2026)
  • Table 470. Mexico Streptococcus Pneumoniae Vaccine, by Distribution Channel USD Million (2021-2026)
  • Table 471. Mexico Streptococcus Pneumoniae Vaccine, by End-User USD Million (2021-2026)
  • Table 472. Streptococcus Pneumoniae Vaccine Sales: by Type(K Units)
  • Table 473. Streptococcus Pneumoniae Vaccine Sales Pneumococcal Conjugate Vaccine (PCV) , by Region K Units (2021-2026)
  • Table 474. Streptococcus Pneumoniae Vaccine Sales Pneumococcal Polysaccharide Vaccine (PPV) , by Region K Units (2021-2026)
  • Table 475. Streptococcus Pneumoniae Vaccine Sales: by Application(K Units)
  • Table 476. Streptococcus Pneumoniae Vaccine Sales Clinics , by Region K Units (2021-2026)
  • Table 477. Streptococcus Pneumoniae Vaccine Sales Hospitals , by Region K Units (2021-2026)
  • Table 478. Streptococcus Pneumoniae Vaccine Sales: by Vaccine Type(K Units)
  • Table 479. Streptococcus Pneumoniae Vaccine Sales Synflorix , by Region K Units (2021-2026)
  • Table 480. Streptococcus Pneumoniae Vaccine Sales Prevnar 13 , by Region K Units (2021-2026)
  • Table 481. Streptococcus Pneumoniae Vaccine Sales Pneumovax 23 , by Region K Units (2021-2026)
  • Table 482. Streptococcus Pneumoniae Vaccine Sales: by Distribution Channel(K Units)
  • Table 483. Streptococcus Pneumoniae Vaccine Sales Governmental Organizations , by Region K Units (2021-2026)
  • Table 484. Streptococcus Pneumoniae Vaccine Sales Non-Government Organizations , by Region K Units (2021-2026)
  • Table 485. Streptococcus Pneumoniae Vaccine Sales: by End-User(K Units)
  • Table 486. Streptococcus Pneumoniae Vaccine Sales Adults Above 65 Years , by Region K Units (2021-2026)
  • Table 487. Streptococcus Pneumoniae Vaccine Sales Children Above 2 Years , by Region K Units (2021-2026)
  • Table 488. South America Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2021-2026)
  • Table 489. South America Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 490. South America Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 491. South America Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 492. South America Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 493. South America Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 494. Brazil Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 495. Brazil Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 496. Brazil Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 497. Brazil Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 498. Brazil Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 499. Argentina Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 500. Argentina Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 501. Argentina Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 502. Argentina Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 503. Argentina Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 504. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 505. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 506. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 507. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 508. Rest of South America Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 509. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2021-2026)
  • Table 510. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 511. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 512. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 513. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 514. Asia Pacific Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 515. China Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 516. China Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 517. China Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 518. China Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 519. China Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 520. Japan Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 521. Japan Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 522. Japan Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 523. Japan Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 524. Japan Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 525. India Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 526. India Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 527. India Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 528. India Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 529. India Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 530. South Korea Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 531. South Korea Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 532. South Korea Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 533. South Korea Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 534. South Korea Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 535. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 536. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 537. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 538. Taiwan Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 539. Taiwan Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 540. Australia Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 541. Australia Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 542. Australia Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 543. Australia Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 544. Australia Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 545. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 546. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 547. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 548. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 549. Rest of Asia-Pacific Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 550. Europe Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2021-2026)
  • Table 551. Europe Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 552. Europe Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 553. Europe Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 554. Europe Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 555. Europe Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 556. Germany Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 557. Germany Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 558. Germany Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 559. Germany Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 560. Germany Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 561. France Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 562. France Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 563. France Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 564. France Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 565. France Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 566. Italy Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 567. Italy Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 568. Italy Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 569. Italy Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 570. Italy Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 571. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 572. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 573. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 574. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 575. United Kingdom Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 576. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 577. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 578. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 579. Netherlands Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 580. Netherlands Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 581. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 582. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 583. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 584. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 585. Rest of Europe Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 586. MEA Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2021-2026)
  • Table 587. MEA Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 588. MEA Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 589. MEA Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 590. MEA Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 591. MEA Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 592. Middle East Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 593. Middle East Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 594. Middle East Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 595. Middle East Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 596. Middle East Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 597. Africa Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 598. Africa Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 599. Africa Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 600. Africa Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 601. Africa Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 602. North America Streptococcus Pneumoniae Vaccine Sales, by Country K Units (2021-2026)
  • Table 603. North America Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 604. North America Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 605. North America Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 606. North America Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 607. North America Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 608. United States Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 609. United States Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 610. United States Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 611. United States Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 612. United States Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 613. Canada Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 614. Canada Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 615. Canada Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 616. Canada Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 617. Canada Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 618. Mexico Streptococcus Pneumoniae Vaccine Sales, by Type K Units (2021-2026)
  • Table 619. Mexico Streptococcus Pneumoniae Vaccine Sales, by Application K Units (2021-2026)
  • Table 620. Mexico Streptococcus Pneumoniae Vaccine Sales, by Vaccine Type K Units (2021-2026)
  • Table 621. Mexico Streptococcus Pneumoniae Vaccine Sales, by Distribution Channel K Units (2021-2026)
  • Table 622. Mexico Streptococcus Pneumoniae Vaccine Sales, by End-User K Units (2021-2026)
  • Table 623. Streptococcus Pneumoniae Vaccine: by Type(USD/Units)
  • Table 624. Research Programs/Design for This Report
  • Table 625. Key Data Information from Secondary Sources
  • Table 626. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Streptococcus Pneumoniae Vaccine: by Type USD Million (2015-2020)
  • Figure 5. Global Streptococcus Pneumoniae Vaccine: by Application USD Million (2015-2020)
  • Figure 6. Global Streptococcus Pneumoniae Vaccine: by Vaccine Type USD Million (2015-2020)
  • Figure 7. Global Streptococcus Pneumoniae Vaccine: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Streptococcus Pneumoniae Vaccine: by End-User USD Million (2015-2020)
  • Figure 9. South America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 10. Asia Pacific Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 11. Europe Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 12. MEA Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 13. North America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 14. Global Streptococcus Pneumoniae Vaccine: by Type K Units (2015-2020)
  • Figure 15. Global Streptococcus Pneumoniae Vaccine: by Application K Units (2015-2020)
  • Figure 16. Global Streptococcus Pneumoniae Vaccine: by Vaccine Type K Units (2015-2020)
  • Figure 17. Global Streptococcus Pneumoniae Vaccine: by Distribution Channel K Units (2015-2020)
  • Figure 18. Global Streptococcus Pneumoniae Vaccine: by End-User K Units (2015-2020)
  • Figure 19. South America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 20. Asia Pacific Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 21. Europe Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 22. MEA Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 23. North America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 24. Global Streptococcus Pneumoniae Vaccine: by Type USD/Units (2015-2020)
  • Figure 25. Global Streptococcus Pneumoniae Vaccine share by Players 2020 (%)
  • Figure 26. Global Streptococcus Pneumoniae Vaccine share by Players (Top 3) 2020(%)
  • Figure 27. Global Streptococcus Pneumoniae Vaccine share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2020
  • Figure 31. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi (France) Revenue: by Geography 2020
  • Figure 33. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Merck Group (Germany) Revenue: by Geography 2020
  • Figure 37. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 39. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 41. Abera (Sweden) Revenue, Net Income and Gross profit
  • Figure 42. Abera (Sweden) Revenue: by Geography 2020
  • Figure 43. S K Chemicals (South Korea) Revenue, Net Income and Gross profit
  • Figure 44. S K Chemicals (South Korea) Revenue: by Geography 2020
  • Figure 45. Beijing Minhai Biotechnology (China) Revenue, Net Income and Gross profit
  • Figure 46. Beijing Minhai Biotechnology (China) Revenue: by Geography 2020
  • Figure 47. Baxter International (United States) Revenue, Net Income and Gross profit
  • Figure 48. Baxter International (United States) Revenue: by Geography 2020
  • Figure 49. BIKEN TECHNO CORPORATION LTD (Japan) Revenue, Net Income and Gross profit
  • Figure 50. BIKEN TECHNO CORPORATION LTD (Japan) Revenue: by Geography 2020
  • Figure 51. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 52. Celgene (United States) Revenue: by Geography 2020
  • Figure 53. Panacea Biotec (India) Revenue, Net Income and Gross profit
  • Figure 54. Panacea Biotec (India) Revenue: by Geography 2020
  • Figure 55. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 56. Serum Institute of India (India) Revenue: by Geography 2020
  • Figure 57. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 58. Genentech (United States) Revenue: by Geography 2020
  • Figure 59. Genocea Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 60. Genocea Biosciences (United States) Revenue: by Geography 2020
  • Figure 61. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 62. Lupin Limited (India) Revenue: by Geography 2020
  • Figure 63. Global Streptococcus Pneumoniae Vaccine: by Type USD Million (2021-2026)
  • Figure 64. Global Streptococcus Pneumoniae Vaccine: by Application USD Million (2021-2026)
  • Figure 65. Global Streptococcus Pneumoniae Vaccine: by Vaccine Type USD Million (2021-2026)
  • Figure 66. Global Streptococcus Pneumoniae Vaccine: by Distribution Channel USD Million (2021-2026)
  • Figure 67. Global Streptococcus Pneumoniae Vaccine: by End-User USD Million (2021-2026)
  • Figure 68. South America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 69. Asia Pacific Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 70. Europe Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 71. MEA Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 72. North America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 73. Global Streptococcus Pneumoniae Vaccine: by Type K Units (2021-2026)
  • Figure 74. Global Streptococcus Pneumoniae Vaccine: by Application K Units (2021-2026)
  • Figure 75. Global Streptococcus Pneumoniae Vaccine: by Vaccine Type K Units (2021-2026)
  • Figure 76. Global Streptococcus Pneumoniae Vaccine: by Distribution Channel K Units (2021-2026)
  • Figure 77. Global Streptococcus Pneumoniae Vaccine: by End-User K Units (2021-2026)
  • Figure 78. South America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 79. Asia Pacific Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 80. Europe Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 81. MEA Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 82. North America Streptococcus Pneumoniae Vaccine Share (%), by Country
  • Figure 83. Global Streptococcus Pneumoniae Vaccine: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Sanofi (France)
  • GSK (United Kingdom)
  • Merck Group (Germany)
  • Eli Lilly and Company (United States)
  • AstraZeneca (United Kingdom)
  • Abera (Sweden)
  • S K Chemicals (South Korea)
  • Beijing Minhai Biotechnology (China)
  • Baxter International (United States)
  • BIKEN TECHNO CORPORATION LTD (Japan)
  • Celgene (United States)
  • Panacea Biotec (India)
  • Serum Institute of India (India)
  • Genentech (United States)
  • Genocea Biosciences (United States)
  • Lupin Limited (India)
Additional players considered in the study are as follows:
Nuron Biotech (United States) , Biogen (United States) , Valneva SE (France) , Sinovac Biotech (China)
Select User Access Type

Key Highlights of Report


Feb 2021 245 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Streptococcus Pneumoniae Vaccine Market Quantitative research analysis
Global Streptococcus Pneumoniae Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Streptococcus Pneumoniae Vaccine market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Streptococcus Pneumoniae Vaccine market are Pfizer (United States), Sanofi (France), GSK (United Kingdom), Merck Group (Germany), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Abera (Sweden), S K Chemicals (South Korea), Beijing Minhai Biotechnology (China), Baxter International (United States), BIKEN TECHNO CORPORATION LTD (Japan), Celgene (United States), Panacea Biotec (India), Serum Institute of India (India), Genentech (United States), Genocea Biosciences (United States) and Lupin Limited (India), to name a few.
In this highly competitive & fast evolving Streptococcus Pneumoniae Vaccine industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Streptococcus Pneumoniae Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Achondroplasty Treatment Drug Comprehensive Study by Type (Lipase Inhibitor, Appetite Suppresants, Human Growth Hormone), Application (Hospital, Clinic, Others), Patient Type (Adult, Paediatric), Dis...
$ 3450
Betahistine Comprehensive Study by Type (8mg, 16mg, 24mg), Application (Vertigo, Tinnitus, Nausea), Sales Channel (Online, Offline) Players and Region - Global Market Outlook to 2026
$ 3500
Pilocarpine Comprehensive Study by Type (Pilocarpine Tablets, Pilocarpine Eye Drops), Application (Dry Mouth, Gluacom or Ocular Hypertension), Distribution Channel (Hospital Pharmacies, Retail Pharma...
$ 3450
Decitabine Drug Comprehensive Study by Type (Prescription, Over-the-Counter), Application (Myelodysplastic syndrome, Acute Myeloid Leukemia), Distribution Channel (Hospital Pharmacies, Drug Store, Re...
$ 3450
Gastric Carcinomas Drugs Comprehensive Study by Drugs (Ramucirumab, Docetaxel, Doxorubicin Hydrochloride, Fluorouracil, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, E-Comme...
$ 3750
Pharyngitis Tablets Comprehensive Study by Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), Source (Viral, Bacterial), Symptoms (Sore Throat, Fever, Runny Nose, Cough, Headache...
$ 3500